Roche Expects China NSCLC Boost For Avastin
This article was originally published in PharmAsia News
Executive Summary
The additional indication for the largest cancer type in China is likely to propel the already fast-growing biologic agent Avastin to a new high, expects Roche COO Daniel O’Day.